BackZhengye Biotechnology Holding Limited Overview

Zhengye Biotechnology Holding Limited Other Current Liabilities

Track Zhengye Biotechnology Holding Limited's other current liabilities ($3.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$3.39M
39.10% YoYΔ $-2.17M vs prior year quarter

Peer trimmed avg / median

Loading

Zhengye Biotechnology Holding Limited Other Current Liabilities History

Loading

Zhengye Biotechnology Holding Limited vs. peers: Other Current Liabilities Comparison

Loading

Zhengye Biotechnology Holding Limited Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Zhengye Biotechnology Holding Limited (ZYBT) FAQ

Zhengye Biotechnology Holding Limited (ZYBT) currently reports a other current liabilities of $3.4M as of December 2025. That compares with $5.6M in the prior-year period — down 39.1% year over year. Use the charts on this page to explore Zhengye Biotechnology Holding Limited's other current liabilities history and peer comparisons.

Zhengye Biotechnology Holding Limited's other current liabilities decreased from $5.6M to $3.4M — a 39.1% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Zhengye Biotechnology Holding Limited reported $3.4M in other current liabilities as of December 2025. That compares with $5.6M in the prior-year period — down 39.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $3.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zhengye Biotechnology Holding Limited, and consider following ZYBT for alerts when major investors trade the stock.